TMSB10 and ovarian carcinoma: Expression of Tβ10 has been shown to confer cell migratory advantage in thyroid carcinoma[17,18,35,36], and melanoma[19,31,37]; but disadvantage in endothelial cells[38] and ovarian cancer[24].